Magnesium compositions and uses thereof for neurological disorders
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-033/16
A61K-033/06
A61K-045/06
A61K-008/19
A61Q-015/00
A23L-033/16
A23L-033/15
출원번호
US-0344466
(2016-11-04)
등록번호
US-9737563
(2017-08-22)
발명자
/ 주소
Liu, Guosong
Mao, Fei
출원인 / 주소
Neurocentria, Inc.
대리인 / 주소
Wilson Sonsini Goodrich & Rosati
인용정보
피인용 횟수 :
0인용 특허 :
26
초록▼
A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of application
A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
대표청구항▼
1. A dosage form formulated for topical administration to a subject, wherein the dosage form comprises magnesium threonate. 2. The dosage form of claim 1, comprising at least 0.1 mg magnesium threonate. 3. The dosage form of claim 1, comprising at least 1 mg magnesium threonate. 4. The dosage form o
1. A dosage form formulated for topical administration to a subject, wherein the dosage form comprises magnesium threonate. 2. The dosage form of claim 1, comprising at least 0.1 mg magnesium threonate. 3. The dosage form of claim 1, comprising at least 1 mg magnesium threonate. 4. The dosage form of claim 1, comprising at least 10 mg magnesium threonate. 5. The dosage form of claim 1, comprising at least 300 mg magnesium threonate. 6. The dosage form of claim 1, comprising about 1.5 mg/kg of body weight/day to about 9 mg/kg of body weight/day elemental magnesium. 7. The dosage form of claim 1, comprising 4% or greater of magnesium by weight. 8. The dosage form of claim 1, comprising 8% or greater of magnesium by weight. 9. The dosage form of claim 1, comprising elemental magnesium at a concentration of from about 5 mg/L to about 12 g/L. 10. The dosage form of claim 1, wherein the dosage form is a liquid, gel, semi-liquid, semi-solid, or solid. 11. The dosage form of claim 1, wherein the dosage form is a tablet, capsule, powder, syrup, slurry, suspension, emulsion, or aerosol. 12. The dosage form of claim 1, further comprising an additional agent. 13. The dosage form of claim 12, wherein the additional agent is selected from the group consisting of an active agent, food additive agent, sweetening agent, flavoring agent, coloring agent, filling agent, binding agent, lubricating agent, excipient, preservative, texturing agent, stabilizing agent, manufacturing agent, and any combination thereof. 14. The dosage form of claim 13, wherein the active agent is selected from the group consisting of a therapeutically active agent, locally active agent, disinfecting agent, cleansing agent, deodorant, fragrance, dye, insect repellent, and any combination thereof. 15. The dosage form of claim 12, wherein the additional agent is selected from the group consisting of a calcium-containing material, stanol ester, hydroxycitric acid, vitamin, mineral, herbal, spice, and any combination thereof. 16. The dosage form of claim 15, wherein the calcium-containing material is calcium carbonate. 17. The dosage form of claim 15, wherein the vitamin is selected from the group consisting of vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin K, niacin, folic acid, biotin, and any combination thereof. 18. The dosage form of claim 15, wherein the mineral is selected from the group consisting of calcium, magnesium, phosphorus, iron, zinc, iodine, selenium, potassium, copper, manganese, molybdenum, and any combination thereof. 19. The dosage form of claim 1, further comprising a pharmaceutically acceptable carrier or excipient. 20. The dosage form of claim 19, wherein the pharmaceutically acceptable excipient is selected from the group consisting of a binder, filler, lubricant, dissolution aid, and any combination thereof. 21. The dosage form of claim 19, wherein the pharmaceutically acceptable excipient is selected from the group consisting of lactose, microcrystalline cellulose, silicon dioxide, titanium dioxide, stearic acid, starch, sodium starch glycolate, povidone, pregelatinized starch, croscarmellose, ethylcellulose, calcium phosphate, talc, sucrose, calcium stearate, hydroxy propyl methylcellulose, shellac, and any combination thereof. 22. The dosage form of claim 1, wherein the dosage form comprises a transdermal patch. 23. The dosage form of claim 1, wherein the dosage form is formulated for or is effective for transdermal administration. 24. A method of delivering magnesium topically to a subject in need thereof, comprising: administering a dosage form of claim 1 to the subject, thereby effecting topical delivery of said magnesium. 25. The method of claim 24, comprising transdermally administering to the subject the dosage form. 26. The method of claim 24, wherein the subject suffers from magnesium deficiency, mild cognitive impairment, Alzheimer's disease, Huntington's disease, autism, schizophrenia, cognitive decline, depression, dementia, attention deficit hyperactivity disorder (ADHD), amyotrophic lateral sclerosis (ALS), Parkinson's disease, diabetes, glaucoma, migraine, anxiety, mood disorder, or hypertension. 27. The method of claim 24, wherein the dosage form comprises 4% or greater of magnesium by weight. 28. The method of claim 24, wherein the dosage form comprises 8% or greater of magnesium by weight. 29. The method of claim 24, wherein the dosage form is administered for at least about 15 days. 30. The method of claim 24, wherein the dosage form is administered for at least about 1 month.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (26)
William T. Evans ; Dwight L. McKee, Alkali or alkaline earth metal of n-butyric acid for treatment of cognitive and emotional conditions.
George H. Clark ; Mary Ann Clark, Carbonated fortified milk-based beverage and method of making carbonated fortified milk-based beverage for the supplementation of essential nutrients in the human diet.
Yu Kai,CNX ; Wang Zhiwen,CNX ; Kou Fuping,CNX, L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof.
Skyler Jay S. (Key Biscayne FL) Frost Phillip (Miami Beach FL) Hahn Elliot F. (North Miami Beach FL), Method and composition for treatment of insulin resistance syndromes.
Glick J. Leslie (Potomac MD), Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory lo.
Atalla Rajai H. (Verona WI) Weinstock Ira A. (Madison WI) Hill Craig L. (Atlanta GA) Reiner Richard S. (Madison WI), Oxidation of lignin and polysaccharides mediated by polyoxometalate treatment of wood pulp.
Costa Jonathan L. (Wheaton IL) Diazgranados Jesus A. (Cali COX), Treatment of human diseases involving dysregulation or dysfunction of the nervous system.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.